Skip to main content
OpenTrials
Completed

NCT Number: NCT06328621

Lung Cancer Risk Assessment and Etiology

This study examines the biological and social determinants that may increase the risk for lung cancer in patients and never-smoking individuals. Biological characteristics of a person can include their genetics and social determinants of a person can include their education, income, and environment, all of which can impact their health. Information collected in this study may help increase early detection of lung cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

City of Hope Medical Center

Duarte, California, 91010, United States

About this study

PRIMARY OBJECTIVE:

I. To assess the frequency of germline cancer susceptibility mutations in affected and unaffected individuals who have a personal or family history suggestive of high lung cancer risk.

EXPLORATORY OBJECTIVES:

I. To assess the frequency of abnormal radiographic findings in high-risk individuals unaffected with cancer who undergo low-dose computed tomography (CT) screening.

II. Use patient survey and medical record data to explore the associations between social determinants of health, biological risk factors, family history and lung cancer incidence.

III. To determine the sensitivity and specificity of liquid biopsy for detection of lung cancer in a never-smoking population.

OUTLINE:

Participants complete a survey over 40-45 minutes at baseline and undergo collection of blood samples at a scheduled clinical or research blood draw. Participants' medical records are also reviewed. Participants not diagnosed with lung cancer (i.e. "unaffected"), undergo a low-dose computerized tomography (CT) scan over 20 minutes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have had clinical germline genetic testing and/or have consented or expressed a willingness to consent to the City of Hope (COH) General Research Protocol COH IRB # 07047
  • Age >= 18 years
  • Willing to have about 30 mL of blood (approximately 2 tablespoons) drawn during the aspiration visit
  • Speak English, Spanish, or Mandarin
  • Lung cancer patients: meeting at least one of the following criteria:
  • Be a never-smoker with lung cancer (excludes atypical/typical carcinoid and small cell tumors)
  • Be diagnosed with lung cancer =< 50 years of age
  • Have a germline alteration known/suspected to be associated with elevated lung cancer risk
  • Have a strong family history of lung cancer (>= one first, second or third degree relative with never-smoking lung cancer, >= three first, second or third degree relative with lung cancer in one lineage [side of the family], >= one first, second or third degree relative diagnosed with lung cancer under the age of 50. Patients may also be considered eligible if they meet the family history criteria in part and have a truncated family structure [e.g., only one first and one second degree relative with lung cancer in a small family])
  • Unaffected patients (i.e., those without a lung cancer diagnosis and other cancer diagnosis for the past 5 years) who are at least 50 years of age or at most age 10 years younger than the first case of lung cancer in the family, meeting at least one of the following criteria:
  • Have a germline alteration known/suspected to be associated with elevated lung cancer risk
  • Have a strong family history of lung cancer (>= one first, second or third degree relative with never-smoking lung cancer, >= three first, second or third degree relative with lung cancer in one lineage [side of the family], >= one first, second or third degree relative diagnosed with lung cancer under the age of 50. Patients may also be considered eligible if they meet the family history criteria in part and have a truncated family structure [e.g., only one first and one second degree relative with lung cancer in a small family])
  • Of East Asian descent with any family history of lung cancer
  • Documented informed consent of the participant

Exclusion criteria

  • Unable to provide informed consent
  • Patients who fall under the unaffected cohort criteria but received chest imaging (except chest x-ray) within the last year

Treatment and study plan

Biospecimen Collection

Procedure

Undergo collection of blood samples

Other names: Biological Sample Collection, Biospecimen Collected, Specimen Collection

Computed Tomography

Procedure

Undergo low-dose CT

Other names: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography

Electronic Health Record Review

Other

Review of medical records

Survey Administration

Other

Complete survey

Primary outcomes

  1. Frequency of germline alterations

    Time frame: Through study completion, an average of 5 years

    We will explore the relationships between variables, examining correlations (Pearson or Spearman where appropriate). Summarization of data using univariate distributions of the outcomes of interest (presence of lung cancer and molecular phenotypes) and their bivariate distributions with social determinants of health will be carried out. We will examine whether financial hardship, low levels of education, and traffic proximity are associated with presence of lung cancer and molecular phenotypes by using T-tests to compare means and Fisher's exact test to compare proportions. We will also conduct logistic regression modeling to adjust for relevant covariates like race/ethnicity, age, and sex. If appropriate, we will use standard techniques such as sensitivity analyses or multiple imputation to handle missing data.

Other outcomes

  1. Frequency of abnormal radiographic findings

    Time frame: Through study completion, an average of 5 years

    Will assess the frequency of abnormal radiographic findings in high-risk individuals unaffected with cancer who undergo low-dose computed tomography (CT) screening. Will summarize data related to the frequency of abnormal radiographic findings in high-risk individuals who undergo low-dose CT screening.

  2. Associations between molecular phenotypes, social determinants of health, and the presence of lung cancer and related outcomes

    Time frame: Up to study completion

    Identification of associations of social determinants of health and risk factors with lung cancer using lung cancer cases and non cases (survey and medical record data).

  3. Liquid biopsy (LB) test sensitivity

    Time frame: Through study completion, an average of 5 years

    Calculated by comparing the LB results with known cancer status. Results will be reported with their corresponding 95% confidence intervals.

  4. LB test specificity

    Time frame: Through study completion, an average of 5 years

    Calculated by comparing the LB results with known cancer status. Results will be reported with their corresponding 95% confidence intervals.

  5. LB test positive predictive value

    Time frame: Through study completion, an average of 5 years

    Calculated by comparing the LB results with known cancer status. Results will be reported with their corresponding 95% confidence intervals.

  6. LB test negative predictive value

    Time frame: Through study completion, an average of 5 years

    Calculated by comparing the LB results with known cancer status. Results will be reported with their corresponding 95% confidence intervals.

  7. LB test accuracy comparing LB genetic mutations to those found on next generation sequencing (NGS)

    Time frame: Through study completion, an average of 5 years

    LB test sensitivity and specificity, will be calculated by comparing the LB results with known cancer status. In addition to sensitivity and specificity, we will also examine other confusion matrix statistics, such as positive predictive value, negative predictive value, and test accuracy. Results will be reported with their corresponding 95% confidence intervals.

Sponsors and collaborators

Lead sponsor

City of Hope Medical Center

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Lung Cancer Risk Assessment &Amp; Etiology

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Mar 25, 2024
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.